Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-16
2011-08-16
Sang, Hong (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100
Reexamination Certificate
active
07999079
ABSTRACT:
This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
REFERENCES:
patent: 4689299 (1987-08-01), Insel et al.
patent: 5306730 (1994-04-01), Nagai et al.
patent: 5599539 (1997-02-01), Carroll et al.
patent: 5719267 (1998-02-01), Carroll et al.
patent: 5731161 (1998-03-01), Aoki et al.
patent: 5807741 (1998-09-01), Brown et al.
patent: 5919665 (1999-07-01), Williams et al.
patent: 5932449 (1999-08-01), Emanuel et al.
patent: 6331402 (2001-12-01), Nussbaum et al.
patent: 6416947 (2002-07-01), Balasubramanian
patent: 6461617 (2002-10-01), Shone et al.
patent: 6495143 (2002-12-01), Lee et al.
patent: 6656468 (2003-12-01), Carroll et al.
patent: 6667158 (2003-12-01), Bavari et al.
patent: 6762280 (2004-07-01), Schmidt et al.
patent: 6794128 (2004-09-01), Marks et al.
patent: 6841156 (2005-01-01), Aioki et al.
patent: 7081529 (2006-07-01), Smith et al.
patent: 7157562 (2007-01-01), Olsen, II et al.
patent: 7192596 (2007-03-01), Shone et al.
patent: 7214787 (2007-05-01), Smith et al.
patent: 7244826 (2007-07-01), Marks et al.
patent: 7563874 (2009-07-01), Marks et al.
patent: 2002/0155114 (2002-10-01), Marks et al.
patent: 2004/0175385 (2004-09-01), Marks et al.
patent: 2004/0265935 (2004-12-01), Atassi
patent: 2006332045 (2006-01-01), None
patent: 2492883 (2005-02-01), None
patent: 1572121 (2005-09-01), None
patent: 06849678.6 (2006-01-01), None
patent: W09625669 (1996-08-01), None
patent: WO0069891 (2000-11-01), None
patent: WO0069895 (2000-11-01), None
patent: WO2004106376 (2004-09-01), None
patent: WO2005016232 (2005-02-01), None
patent: WO2005084361 (2005-09-01), None
patent: WO2007094754 (2006-01-01), None
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.
Rudikoff et al., Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982.
Colman, Research in Immunology, 145:33-36, 1994.
Bendig, Methods: A Companion to Methods in Enzymology, 1995; 8:83-93.
Almquist, et al, Vaccine, 2005, Expression of an anti-botulinum toxin A neutralizing single-chain Fv recombinant antibody in transgenic tobacco, 24 (12): 2079-2086.
Amersdorfer, et al., Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries(1997) Infect. , 65: 3743-3752.
Amersdorfer, et al., Phage Libraries for Generation of Anti-Botulinum scFv Antibodies, (2000) Meth. Mol Biol. 145 : 219-240.
Amersdorfer, et al., Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries., Vaccine. Feb. 22, 2002;20(11-12):1640-1648.
Arnon, et al., Botulinum toxin as biological weapon: medical and public health management., Journal of the American Medical Association. Feb. 28, 2001, 285 (8):1059-1070.
Arnon, et al., Amon SS. 1993. In Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects (DasGupta, BR, Ed.) pp. 477-482.
Atassi, et al., Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species., J. Protein Chem., vol. 15, 691-699, 1996.
Baldwin, et al., Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E., Infect Immun. Oct. 2005;73(10):6998-7005.
Bartels, et al., Specific antibodies against the Zn(2+)-binding domain of clostridial neurotoxins restore exocytosis in chromaffin cells treated with tetanus or botulinum a neurotoxin., Mar. 18, 1994, The Journal of Biological Chemistry, 269, 8122-8127.
Bavari, et al., Identifying the principal protective antigenic determinants of type A botulinum neurotoxin., Vaccine vol. 16, Issue 19, Nov. 1998, pp. 1850-1856.
Black, et al., Hypersensitivity reactions associated with botulinal antitoxin., vol. 69, Issue 4, pp. 567-570, Oct. 1980.
Black, et al., Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves., J Cell Biol. Aug. 1, 1986; 103(2): 521-534.
Bowmer, Ernest, J., Preparation and Assay of the International Standards for Clostridium Botulinum Types A, B, C, D and E Antitoxins., Bull World Health Organ. 1963;29:701-709.
Byrne, et al., Development of vaccines for prevention of botulism., Biochimie. Sep.-Oct. 2000;82(9-10):955-966.
Chen, et al., Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms., Infect Immun. May 1997;65(5):1626-1630.
Chen, et al., Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species., Infect Immun. Jun. 1998;66(6):2420-2425.
Colcher, et al., In vivo tumor targeting of a recombinant single-chain antigen-binding protein., JNCI Journal of the National Cancer Institute 1990 82(14):1191-1197.
Coleman, et al., Methods: recombinant dna technology, FASEB Journal, 2004, 18/8, Suppl. S. p. C174, meeting abstract.
Daniels-Holgate, et al., Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain., J Neurosci Res. May 1, 1996;44(3):263-271.
Demarchi, et al., Existence du botulisme humain de type D., Bull Acad Natl Med. 142(21-22):580-582, 1958.
Dixit, et al., Development of an immunodetection test for a botulinum-like neurotoxin produced by Clostridium sp. RKD., Indian J Med Res. Sep. 2006;124(3):355-362.
Dixit, et al., Characterization of clostridium sp. RKD producing botulinum-like neurotoxin., Syst Appl Microbiol. Jul. 2005;28(5):405-414.
Doellgast, et al., Sensitive assay for measurement of antibodies of clostridium botulinum neurotoxins A, B, and E: use of hapten-labeled-antibody elution to isolate specific complexes., Journal of Clinical Microbiology, Mar. 1997, 578-583, vol. 35, No. 3.
Doellgast, et al., Sensitive enzyme-linked immunosorbent assay for detection of Clostridium botulinum neurotoxins A, B, and E using signal amplification via enzyme-linked coagulation assay., J Clin Microbiol. Sep. 31, 1993; 31(9): 2402-2409.
Dolimbek, et al., Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin., Mol. Immunology, Sep. 24, 2007.
Dolly, et a., Acceptors for botulinum neurotoxins reside on motor nerve terminals and mediate its internalization., Nature 307, 457-460, Feb. 2, 1984.
Emanuel, et al., Directing antigen specificity towards botulinum neurotoxin with combinatorial phage display libraries.,vol. 193, Issue 2, Jun. 21, 1996, pp. 189-197.
Emanuel, et al., Directing antigen specificity towards botulinum neurotoxin with combinatorial phage display libraries., Journal of immunological methods, 1996, vol. 193, No. 2, pp. 189-197.
Fitzsimmons, et al., Inhibition of tetanus toxin fragment C binding to ganglioside G(T1b) by monoclonal antibodies recognizing different epitopes., Vaccine. Aug. 15, 2000;19(1):114-121.
Foote, et al., Kinetic maturation of an immune response., Nature 352, 530-532, Aug. 8, 1991.
Fontinou, et al.,The Crystal Structure of Tetanus Toxin Hc Fragment Complexed with a Synthetic GT1b Analogue Suggests Cross-linking between Ganglioside Receptors and the Toxin., Journal of Biological Chemistry, 276, 32274-32281, Aug. 24, 2001.
Franz, et al.,Efficacy of prophylactic and therapeutic administration of antitoxin for inhalational botulism., Botulinum and tetanus neurotoxins, B.R. DasGupta, Plenum press, NY, 1993.
Garcia, et al., Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin., Nature Biotechnology 25, 107-116 (2006).
Gibson, et al., Evaluation of a monoclonal antibody-based immunoassay for detecting type B Clostridium botulinum toxin produced in pure culture and an
Amersdorfer Peter
Garcia Maria Consuelo
Geren Isin
Lou Jianlong
Marks James D.
Bozicevic Field & Francis LLP
Francis Carol L.
Sang Hong
The Regents of the University of California
LandOfFree
Therapeutic monoclonal antibodies that neutralize botulinum... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic monoclonal antibodies that neutralize botulinum..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic monoclonal antibodies that neutralize botulinum... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2766633